# A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176

> **NCT02715479** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 14 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus

## Interventions

- **DRUG:** Dolutegravir
- **DRUG:** BMS955176

## Key facts

- **NCT ID:** NCT02715479
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2017-01-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02715479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02715479, "A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02715479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*